Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma

British Journal of Haematology

Volumn 138, Issue 3, 2007, Pages 324-329

  Chang, Hong ^a,b   Yeung, Joanna ^a   Qi, Connie ^a   Xu, Wei ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Fluorescence in situ hybridisation; Immunohistochemistry; Myeloma; p53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC RISK; HEMIZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL;

ADULT; AGED; CELL NUCLEUS; FEMALE; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447122014     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06649.x     Document Type: Article

References (31)

1. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C.A., Gannon, J.V. Lane, D.P. (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6, 1699 1703.
2. Bullock, A.N. Fersht, A.R. (2001) Rescuing the function of mutant p53. Nature Reviews Cancer, 1, 68 76.
3. Chang, H., Bouman, D., Boerkoel, C.F., Stewart, A.K. Squire, J.A. (1999) Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia, 13, 105 109.
4. Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q.L., Chen, C.I., Reece, D., Chun, K. Stewart, K.A. (2004a) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology, 125, 64 68.
5. Chang, H., Sloan, S., Li, D. Stewart, A.K. (2004b) Multiple myeloma involving central nervous system: high frequency of p53 deletions. British Journal of Haematology, 127, 280 284.
6. Chang, H., Qi, C., Yi, Q.L., Reece, D. Stewart, A.K. (2005a) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood, 105, 358 360.
7. Chang, H., Stewart, A.K., Qi, X.Y., Li, Z.H., Yi, Q.L. Trudel, S. (2005b) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood, 106, 353 355.
8. Chang, H., Samiee, S., Qi, W.Y., Yi, Q.L., Mikhael, J., Chen, C., Trudel, S., Mikhael, J., Reece, D. Stewart, A.K. (2005c) Genetic risk identifies myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplantation, 36, 793 796.
9. Chang, H., Qi, X.Y., Trieu, Y., Xu, W., Reeder, R.C., Ning, Y. Reece, D. (2006) Multiple myeloma patients with CKS1B amplification have a poor progression free survival post-autologous stem cell transplantation. British Journal of Haematology, 135, 486 491.
10. Chng, W.J., Price-Troska, T., Gonzalez-Paz, N., Van Wier, S., Jacobus, S., Blood, E., Henderson, K., Oken, M., Van Ness, B., Greipp, P., Rajkumar, S.V. Fonseca, R. (2007) Clinical significance of TP53 mutation in myeloma. Leukemia, 21, 582 584.
11. Drach, J., Ackermann, J., Fritz, E., Kromer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H. Huber, H. (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood, 92, 802 809.
12. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., Lai, J.L., Leleu, X., Jouet, J.P., Bauters, F., Harousseau, J.L., Bataille, R., Mary, J.Y. Intergroupe Francophone du Myelome 2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta-2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97, 1566 1571.
13. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., Van Ness, B., Van Weir, S.A., Henderson, K.J., Bailey, R.J. Greipp, P.R. (2003) Clinical biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569 4575.
14. Gannon, J.V., Greaves, R., Lggo, R. Lane, D.P. (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO Journal, 9, 1595 1602.
15. Hanamura, I., Stewart, J.P., Huang, Y., Zhan, F., Santra, M., Sawyer, J.R., Hollmig, K., Zangarri, M., Pineda-Roman, M., van Rhee, F., Cavallo, F., Burington, B., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, J.D. (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood, 108, 1724 1732.
16. Imamura, J., Miyoshi, I. Koeffler, H.P. (1994) p53 in hematologic malignancies. Blood, 84, 2412 2421.
17. Kyle, R.A. Rajkumar, S.V. (2004) Multiple myeloma. New England Journal of Medicine, 351, 1860 1873.
18. Lai, R., Medeiros, L.J., Wilson, C.S., Sun, N.C., Koo, C., McCourty, A. Brynes, R.K. (1998) Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin D1 immunoreactivity. Modern Pathology, 11, 642 647.
19. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15 16.
20. Lepelley, P., Preudhomme, C., Vanrumbeke, M., Quesnel, B., Cosson, A. Fenaux, P. (1994) Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 8, 1342 1349.
21. Levine, A.J., Momand, J. Finay, C.A. (1991) The p53 tumor suppressor gene. Nature, 351, 453 456.
22. Lowe, S.W. Sherr, C.J. (2003) Tumor suppression by Ink4a-ARF: progress and puzzles. Current Opinion in Genetics Development, 13, 77 83.
23. Markovic, O., Marisavljevic, D., Cemerikic, V., Suvajdzic, N., Milic, N. Colovic, M. (2004) Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance. Medical Oncology, 21, 73 80.
24. Matsushima, A.Y., Cesarman, E., Chadburn, A. Knowles, D.M. (1994) Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. American Journal of Pathology, 144, 573 584.
25. Moll, U.M. Petrenko, O. (2003) The MDM2-p53 interaction. Molecular Cancer Research, 1, 1001 1008.
26. Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.L., Bataille, R., Avet-Loiseau, H. Intergroupe Francophone du Myelome 2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood, 100, 1579 1583.
27. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Welson, A., Modali, R., Harris, C.C. Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature, 342, 705 708.
28. Pruneri, G., Carboni, N., Baldini, L., Intini, D., Colombi, M., Bertolini, F., Valentini, S., Maisonneuve, P., Viale, G. Neri, A. (2003) Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Human Pathology, 34, 41 47.
29. Rassidakis, G.Z., Thomaides, A., Wang, S., Jiang, Y., Fourtouna, A., Lai, R. Medeiros, L.J. (2005) p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia, 19, 1663 1669.
30. Villuendas, R., Piris, M.A., Algara, P., Sanchez-Beato, M., Sanchez-Verde, L., Martinez, J.C., Orradre, J.L., Garcia, P., Lopez, C. Martinez, P. (1993) The expression of p53 protein in non-Hodgkin's lymphoma is not always dependent on p53 mutations. Blood, 82, 3151 3156.
31. Vousden, K.H. (2002) Activation of the p53 tumor suppressor protein. Biochimica et Biophysica Acta, 1602, 47 59.